Haemonetics upgraded by Raymond James with a new price target
$HAE
Medical/Dental Instruments
Health Care
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $120.00 | Outperform → Strong Buy | Raymond James |
| 9/13/2024 | $116.00 | Buy | CL King |
| 9/11/2024 | $85.00 | Neutral | BofA Securities |
| 9/10/2024 | $112.00 | Buy | BTIG Research |
| 6/12/2024 | $112.00 | Hold → Buy | Needham |
| 10/13/2022 | $90.00 | Buy | Mizuho |
| 2/9/2022 | $70.00 → $66.00 | Outperform | Raymond James |
| 1/27/2022 | Buy → Hold | Needham |
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
10-Q - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes the reduction in lower-margin Plasma sales to CSL and the expansion of higher-margin Interventional Technologies sale
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Matson upgraded the rating for Haemonetics Corporation (NYSE:HAE) from Hold to Buy and announced a price target of $112. Haemonetics shares fell 2.8% to close at $83.41 on Tuesday. See how other analysts view this stock. Morgan Stanley analyst Meta Marshall upgraded Ciena Corporation (NYSE:CIEN) from Equal-Weight to Overweight, while raising the price target from $53 to $55. Ciena shares rose 0.2% to settle at $45.92 on Tuesday. See how other analysts view this sto
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
Financial release accessible online BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI5ac87cebabbb4a7aaaad3
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00
CL King initiated coverage of Haemonetics with a rating of Buy and set a new price target of $116.00
BofA Securities initiated coverage of Haemonetics with a rating of Neutral and set a new price target of $85.00
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a